




PHARMACEUTICAL 2021

Zoetis Inc.
Rank 236 of 402





RealRate

PHARMACEUTICAL 2021

Zoetis Inc.
Rank 236 of 402



The relative strengths and weaknesses of Zoetis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zoetis Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Zoetis Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is 69%, being 22% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	6,611,000
Cost of Goods Sold	2,057,000
Intangible Assets	4,404,000
Liabilities, Current	2,170,000
Liabilities, Non-Current	7,028,000
Other Assets	392,000
Other Compr. Net Income	-2,000
Other Expenses	776,000
Other Liabilities	638,000
Other Net Income	-17,000
Other Revenues	6,675,000
Property and Equipment	2,202,000
Research and Development	463,000
Selling, General and Administrative Expense	1,726,000

Output Variable	Value in 1000 USD
Assets	13,609,000
Liabilities	9,836,000
Expenses	5,022,000
Revenues	6,675,000
Stockholders Equity	3,773,000
Net Income	1,636,000
Comprehensive Net Income	1,635,000
Economic Capital Ratio	69%